nach oben

Rheumatology International

Erschienen in:

23.05.2018 | Review

The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease

verfasst von: Alina Dima, Ciprian Jurcut, Cristian Baicus

Erschienen in: Rheumatology International | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Anti-U1-RNP positivity remains mandatory for the mixed connective tissue disease (MCTD) diagnosis, reason for which anti-U1-RNP occurrence in patients with lupus clinical features might determine diagnostic issues. Thus, the prevalence of 25–30% for anti-RNP was reported in John Hopkins and LUMINA lupus cohorts and also 13% prevalence for the anti-U1-RNP in Euro-Lupus cohort. Presence of anti-U1-RNP antibodies in patients fulfilling SLE criteria (but not the MCTD ones) was associated with manifestations such as Raynaud phenomenon, musculoskeletal and lung impairment or nail fold capillaroscopy changes, some clinical features frequently encountered in MCTD patients and only rarely described in lupus population. The use of more specific markers such as 70 kDa anti-U1-RNP or anti-Sm-D was proposed for discriminating between SLE and MCTD. In addition, the IgM serotype of anti-U1-RNP seems more frequently expressed in SLE, while the IgG serotype alone in MCTD. Better acknowledgement of possible clinical involvements in lupus subsets, such as the peculiarities related to the anti-U1-RNP positivity, could provide access to early diagnosis of rather rare but possible severe lupus organ impairments (e.g. pulmonary arterial hypertension).

Cervera R, Khamashta M, Hughes G (2009) The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. Lupus 18(10):869–874. https://doi.org/10.1177/0961203309106831 CrossRefPubMed

To CH, Petri M (2005) Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? Arthritis Rheum 52:4003–4010. https://doi.org/10.1002/art.21414 CrossRefPubMed

Bertoli AM, Vila LM, Apte M et al (2007) Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: factors predictive of pulmonary damage. Lupus 16:410–417. https://doi.org/10.1177/0961203307079042 CrossRefPubMed

Boddaert J, Huong DLT, Amoura Z et al (2004) Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine (Baltimore) 83:348–359CrossRef

Mattioli M, Reichlin M (1971) Characterization of a soluble nuclear ribonucleoprotein antigen reactive with SLE sera. J Immunol 107:1281–1290PubMed

Benito-Garcia E, Schur PH, Lahita R et al (2004) Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-Sm and anti-RNP antibody tests. Arthritis Rheum 51:1030–1044. https://doi.org/10.1002/art.20836 CrossRefPubMed

Tan EM, Kunkel HG (1966) Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus. J Immunol 96:464–471PubMed

Poole BD, Schneider RI, Guthridge JM et al (2009) Early targets of nuclear RNP humoral autoimmunity in human systemic lupus erythematosus. Arthritis Rheum 60:848–859. https://doi.org/10.1002/art.24306 CrossRefPubMedPubMedCentral

Amigues JM, Cantagrel A, Abbal M et al (1996) Comparative study of 4 diagnosis criteria sets for mixed connective tissue disease in patients with anti-RNP antibodies. Autoimmunity Group of the Hospitals of Toulouse. J Rheumatol 23:2055–2062PubMed

10.

Cappelli S, Bellando RS, Martinović D et al (2012) “To be or not to be,” ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum 41:589–98. https://doi.org/10.1016/j.semarthrit.2011.07.010 CrossRefPubMed

11.

Alarcón-Segovia D, Cardiel MH (1989) Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol 16:328–334PubMed

12.

Mesa A, Somarelli JA, Wu W et al (2013) Differential immunoglobulin class-mediated responses to components of the U1 small nuclear ribonucleoprotein particle in systemic lupus erythematosus and mixed connective tissue disease. Lupus 22:1371–1381. https://doi.org/10.1177/0961203313508444 CrossRefPubMed

13.

Hoffman RW, Bezruczko N, Perkins K (2012) An external validation study of a classification of mixed connective tissue disease and systemic lupus erythematosus patients. J Appl Meas 13:205–216PubMed

14.

Gordon C, Amissah-Arthur M-B, Gayed M et al (2017) The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology 57:e1–e45. https://doi.org/10.1093/rheumatology/kex286 CrossRef

15.

Bertsias G, Ioannidis JPA, Boletis J et al (2008) EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67:195–205. https://doi.org/10.1136/ard.2007.070367 CrossRefPubMed

16.

Cozzani E, Drosera M, Gasparini G et al (2014) Serology of lupus erythematosus: correlation between immunopathological features and clinical aspects. Autoimmune Dis 2014:321359. https://doi.org/10.1155/2014/321359 PubMedPubMedCentralCrossRef

17.

Artim-Esen B, Cene E, ahinkaya Y et al (2014) Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center. J Rheumatol 41:1304–1310. https://doi.org/10.3899/jrheum.130984 CrossRefPubMed

18.

Vencovsky J, Williams DG, Field M et al (1992) Clinical associations of IgG antibodies to the ribonucleoprotein p67 polypeptide in patients with systemic lupus erythematosus. Ann Rheum Dis 51:1313–1317CrossRefPubMedPubMedCentral

19.

Ter Borg EJ, Groen H, Horst G et al (1990) Clinical associations of antiribonucleoprotein antibodies in patients with systemic lupus erythematosus. Semin Arthritis Rheum 20:164–173CrossRefPubMed

20.

Furtado RNV, Pucinelli MLC, Cristo VV et al (2002) Scleroderma-like nailfold capillaroscopic abnormalities are associated with anti-U1-RNP antibodies and Raynaud’s phenomenon in SLE patients. Lupus 11:35–41CrossRefPubMed

21.

Heimovski FE, Simioni JA, Skare TL (2015) Systemic lupus erythematosus and Raynaud’s phenomenon. An Bras Dermatol 90:837–840. https://doi.org/10.1590/abd1806-4841.20153881 CrossRefPubMedPubMedCentral

22.

Frodlund M, Dahlström Ö, Kastbom A et al (2013) Associations between antinuclear antibody staining patterns and clinical features of systemic lupus erythematosus: analysis of a regional Swedish register. BMJ Open 3:e003608. https://doi.org/10.1136/bmjopen-2013-003608 CrossRefPubMedPubMedCentral

23.

Egner W (2000) The use of laboratory tests in the diagnosis of SLE. J Clin Pathol 53:424–432. https://doi.org/10.1136/jcp.53.6.424 CrossRefPubMedPubMedCentral

24.

Munroe ME, Vista ES, Merrill JT et al (2017) Pathways of impending disease flare in African-American systemic lupus erythematosus patients. J Autoimmun. https://doi.org/10.1016/j.jaut.2016.12.005 PubMedPubMedCentralCrossRef

25.

Craft J (1992) Antibodies to snRNPs in systemic lupus erythematosus. Rheum Dis Clin North Am 18:311–335PubMed

26.

Kelly-Scumpia KM, Nacionales DC, Scumpia PO et al (2007) In vivo adjuvant activity of the RNA component of the Sm/RNP lupus autoantigen. Arthritis Rheum 56:3379–3386. https://doi.org/10.1002/art.22946 CrossRefPubMed

27.

Vlachoyiannopoulos PG, Guialis A, Tzioufas G et al (1996) Predominance of IgM anti-U1RNP antibodies in patients with systemic lupus erythematosus. Br J Rheumatol 35:534–541CrossRefPubMed

28.

Migliorini P, Baldini C, Rocchi V et al (2005) Anti-Sm and anti-RNP antibodies. Autoimmunity 38:47–54. https://doi.org/10.1080/08916930400022715 CrossRefPubMed

29.

Mahler M, Waka A, Hiepe F et al (2007) Effect of dsDNA binding to SmD-derived peptides on clinical accuracy in the diagnosis of systemic lupus erythematosus. Arthritis Res Ther 9:R68. https://doi.org/10.1186/ar2266 CrossRefPubMedPubMedCentral

30.

Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725. https://doi.org/10.1002/1529-013(199709)40:9<1725::AID-ART29>3.0.CO;2-Y CrossRefPubMed

31.

Petri M, Orbai AM, Alarcon GS et al (2012) Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686. https://doi.org/10.1002/art.34473 CrossRefPubMedPubMedCentral

32.

Mahler M, Stinton LM, Fritzler MJ (2005) Improved serological differentiation between systemic lupus erythematosus and mixed connective tissue disease by use of an SmD3 peptide-based immunoassay. Clin Diagn Lab Immunol 12:107–113. https://doi.org/10.1128/CDLI.12.1.107-113.2005 PubMedPubMedCentralCrossRef

33.

Salmhofer W, Hermann J, Joch M et al (2007) High serum levels of antibodies against the recombinant 70 kDa ribonucleoprotein are useful for diagnosing mixed connective tissue disease. J Eur Acad Dermatol Venereol 21:1047–1053. https://doi.org/10.1111/j.1468-3083.2007.02163.x CrossRefPubMed

34.

Ishizaki J, Saito K, Nawata M et al (2015) Low complements and high titre of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus. Rheumatology 54:405–412. https://doi.org/10.1093/rheumatology/keu343 CrossRefPubMed

35.

Gunnarsson R, Hetlevik SO, Lilleby V et al (2016) Mixed connective tissue disease. Best Pract Res Clin Rheumatol 30:95–111. https://doi.org/10.1016/j.berh.2016.03.002 CrossRefPubMed

36.

Hoffman RW, Sharp GC, Deutscher SL (1995) Analysis of anti-U1 RNA antibodies in patients with connective tissue disease. Association with HLA and clinical manifestations of disease. Arthritis Rheum 38:1837–1844CrossRefPubMed

37.

Gaubitz M, Wegmann C, Schotte H et al (2002) Differentiation of RNP- and SM-antibody subsets in SLE and MCTD patients by a new ELISA using recombinant antigens. Cell Mol Biol (Noisy-le-grand) 48:317–321

38.

Hoffman IEa, Peene I, Meheus L et al (2004) Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis 63:1155–1158. https://doi.org/10.1136/ard.2003.013417 CrossRefPubMedPubMedCentral

39.

Kattah NH, Kattah MG, Utz PJ (2010) The U1-snRNP complex: structural properties relating to autoimmune pathogenesis in rheumatic diseases. Immunol Rev 233:126–145. https://doi.org/10.1111/j.0105-2896.2009.00863.x CrossRefPubMedPubMedCentral

40.

Bourn R, James JA (2015) Preclinical lupus. Curr Opin Rheumatol 27:433–439. https://doi.org/10.1097/BOR.0000000000000199 CrossRefPubMedPubMedCentral

41.

Berens-Norman HM, Boackle SA. Editorial (2016) Subduing lupus: can preclinical autoimmune disease be arrested? Arthritis Rheumatol 68:2357–2360. https://doi.org/10.1002/art.39804 CrossRefPubMedPubMedCentral

42.

Arbuckle MR, McClain MT, Rubertone MV et al (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349:1526–1533. https://doi.org/10.1056/NEJMoa021933 CrossRefPubMed

43.

Sharp GC, Irvin WS, LaRoque RL et al (1971) Association of autoantibodies to different nuclear antigens with clinical patterns of rheumatic disease and responsiveness to therapy. J Clin Invest 50:350–359. https://doi.org/10.1172/JCI106502 CrossRefPubMedPubMedCentral

44.

Sharp GC, Irvin WS, Tan EM et al (1972) Mixed connective tissue disease–an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 52:148–159CrossRefPubMed

45.

Yoshida K, Inoue H, Komai K et al (2013) Mixed connective tissue disease is distinct from systemic lupus erythematosus: study of major histocompatibility complex class I polypeptide-related sequence A and HLA gene polymorphisms. Tissue Antigens 81:44–45. https://doi.org/10.1111/tan.12027 CrossRefPubMed

46.

Washio M, Fujii T, Kuwana M et al (2014) Lifestyle and other related factors for the development of mixed connective tissue disease among Japanese females in comparison with systemic lupus erythematosus. Mod Rheumatol 24:788–792. https://doi.org/10.3109/14397595.2013.863442 CrossRefPubMed

47.

Mesa A, Fernandez M, Wu W et al (2016) Can SLE classification rules be effectively applied to diagnose unclear SLE cases? Lupus 26:150–162. https://doi.org/10.1177/0961203316655212 CrossRefPubMed

48.

Carpintero MF, Martinez L, Fernandez I et al (2015) Diagnosis and risk stratification in patients with anti-RNP autoimmunity. Lupus 24:1057–1066. https://doi.org/10.1177/0961203315575586 CrossRefPubMedPubMedCentral

49.

Guffroy A, Dima A, Nespola B et al (2016) Anti-pseudo-PCNA type 1 (anti-SG2NA) pattern: Track down Cancer, not SLE. Jt Bone Spine 83:330–334. https://doi.org/10.1016/j.jbspin.2015.07.002 CrossRef

50.

Miyamae T, Ito S, Machida H et al (2008) Clinical features and laboratory findings in children with both anti-dsDNA and anti-U1-RNP antibody. Nihon Rinsho Meneki Gakkai Kaishi 31:405–414CrossRefPubMed

51.

Ching KH, Burbelo PD, Tipton C et al (2012) Two major autoantibody clusters in systemic lupus erythematosus. PLoS One 7:e32001. https://doi.org/10.1371/journal.pone.0032001 CrossRefPubMedPubMedCentral

52.

Jurencák R, Fritzler M, Tyrrell P et al (2009) Autoantibodies in pediatric systemic lupus erythematosus: ethnic grouping, cluster analysis, and clinical correlations. J Rheumatol 36:416–421. https://doi.org/10.3899/jrheum.080588 CrossRefPubMed

53.

Alba P, Bento L, Cuadrado MJ et al (2003) Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis 62:556–560CrossRefPubMedPubMedCentral

54.

Bastian H, Roseman J, Mcgwin G et al (2002) Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 11(3):152–160. https://doi.org/10.1191/0961203302lu158oa CrossRefPubMed

55.

Maverakis E, Patel F, Kronenberg DG et al (2014) International consensus criteria for the diagnosis of Raynaud’s phenomenon. J Autoimmun 48–49:60–65. https://doi.org/10.1016/j.jaut.2014.01.020 CrossRefPubMed

56.

Pavlov-Dolijanovic S, Damjanov NS, Vujasinovic Stupar NZ et al (2013) Is there a difference in systemic lupus erythematosus with and without Raynaud’s phenomenon? Rheumatol Int 33:859–865. https://doi.org/10.1007/s00296-012-2449-6 CrossRefPubMed

57.

Pavlov-Dolijanovic S, Damjanov NS, Stojanovic RM et al (2012) Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a follow-up study of 3,029 patients with primary Raynaud’s phenomenon. Rheumatol Int 32:3039–3045. https://doi.org/10.1007/s00296-011-2109-2 CrossRefPubMed

58.

Huang C, Li M, Liu Y et al Baseline characteristics and risk factors of pulmonary arterial hypertension in systemic lupus erythematosus patients. https://doi.org/10.1097/MD.0000000000002761

59.

Hachulla E, Jais X, Cinquetti G et al (2018) Pulmonary arterial hypertension associated with systemic lupus erythematosus. Chest 153(1):143–151. https://doi.org/10.1016/j.chest.2017.08.014 CrossRefPubMed

60.

Zhao J, Wang Q, Liu Y et al (2017) Clinical characteristics and survival of pulmonary arterial hypertension associated with three major connective tissue diseases: A cohort study in China. Int J Cardiol 236:432–437. https://doi.org/10.1016/j.ijcard.2017.01.097 CrossRefPubMed

61.

Yang X, Mardekian J, Sanders KN et al (2013) Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature. Clin Rheumatol 32:1519–1531. https://doi.org/10.1007/s10067-013-2307-2 CrossRefPubMedPubMedCentral

62.

Tselios K, Gladman D, Urowitz M (2016) Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies. Open Access Rheumatol Res Rev 9:1–9. https://doi.org/10.2147/OARRR.S123549 CrossRef

63.

Tellier S, Bader-Meunier B, Quartier P et al (2016) Initial presentation and outcome of pediatric-onset mixed connective tissue disease: A French multicenter retrospective study. Jt Bone Spine 83:369–371. https://doi.org/10.1016/j.jbspin.2015.05.013 CrossRef

64.

Sibilia J, Chatelus E, Meyer A et al (2010) Comment faire le diagnostic et mieux comprendre les myopathies inflammatoires ? L’utilité des auto-anticorps. Presse Med 39:1010–1025. https://doi.org/10.1016/j.lpm.2010.06.008 CrossRefPubMed

65.

Sato T, Fujii T, Yokoyama T et al (2010) Anti-U1 RNP antibodies in cerebrospinal fluid are associated with central neuropsychiatric manifestations in systemic lupus erythematosus and mixed connective tissue disease. Arthritis Rheum 62:3730–3740. https://doi.org/10.1002/art.27700 CrossRefPubMed

66.

Fujii T (2014) Direct and indirect pathogenic roles of autoantibodies in systemic autoimmune diseases. Allergol Int 63:515–522. https://doi.org/10.2332/allergolint.14-RAI-0801 CrossRefPubMed

67.

Katsumata Y, Kawaguchi Y, Baba S et al (2013) Serum antibodies against the 70 k polypeptides of the U1 ribonucleoprotein complex are associated with psychiatric syndromes in systemic lupus erythematosus: a retrospective study. Mod Rheumatol 23:71–80. https://doi.org/10.1007/s10165-012-0624-y CrossRefPubMed

68.

Reichlin M, Broyles TF, Hubscher O et al (1999) Prevalence of autoantibodies to ribosomal P proteins in juvenile-onset systemic lupus erythematosus compared with the adult disease. Arthritis Rheum 42:69–75. https://doi.org/10.1002/1529-0131(199901)42:1<69::AID-ANR9>3.0.CO;2-J CrossRefPubMed

69.

Ho KT, Reveille JD (2003) The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 5:80–93PubMedPubMedCentral

70.

Asano Y, Ihn H, Yamane K et al (2003) The prevalence and clinical significance of anti-U1 RNA antibodies in patients with systemic sclerosis. J Invest Dermatol 120:204–210. https://doi.org/10.1046/j.1523-1747.2003.12028.x CrossRefPubMed

71.

Assassi S, Mayes MD, Arnett FC et al (2010) Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum 62:589–598. https://doi.org/10.1002/art.27224 CrossRefPubMedPubMedCentral

72.

Hamaguchi Y, Hasegawa M, Fujimoto M et al (2008) The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol 158:487–495. https://doi.org/10.1111/j.1365-2133.2007.08392.x CrossRefPubMedPubMedCentral

73.

Escolà-Vergé L, Pinal-Fernandez I, Fernandez-Codina A et al (2017) Mixed connective tissue disease and epitope spreading. J Clin Rheumatol 23:155–159. https://doi.org/10.1097/RHU.0000000000000500 CrossRefPubMed

Titel: The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease
verfasst von: Alina Dima
Ciprian Jurcut
Cristian Baicus
Publikationsdatum: 23.05.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Rheumatology International / Ausgabe 7/2018
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-018-4059-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2018

Carpal tunnel syndrome treatment with palmitoylethanolamide: neurophysiology and ultrasound show small changes in the median nerve

Improvement of neurological and ocular symptoms of Behçet’s disease after the introduction of infliximab

Patients with systemic rheumatic diseases admitted to the intensive care unit: what the rheumatologist needs to know

Dynamic of changes in coronary artery calcification in early rheumatoid arthritis patients over 18 months

Juvenile idiopathic arthritis in the biologic era: predictors of the disease progression and need for early introduction of biologic treatment

Cardiovascular system changes in rheumatoid arthritis patients with continued low disease activity

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin